NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Given Consensus Rating of “Hold” by Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been given an average recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $11.6667.

NMTC has been the topic of several recent research reports. Weiss Ratings raised NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. LADENBURG THALM/SH SH boosted their price target on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th.

NeuroOne Medical Technologies Stock Performance

NASDAQ:NMTC opened at $1.65 on Thursday. The firm has a 50-day simple moving average of $3.01 and a 200-day simple moving average of $4.08. NeuroOne Medical Technologies has a one year low of $1.61 and a one year high of $6.96. The firm has a market cap of $14.36 million, a P/E ratio of -1.94 and a beta of 0.54.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The business had revenue of $1.86 million for the quarter, compared to the consensus estimate of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 99.43%. On average, research analysts predict that NeuroOne Medical Technologies will post -0.36 EPS for the current fiscal year.

Insider Transactions at NeuroOne Medical Technologies

In other NeuroOne Medical Technologies news, Director Mark Christianson sold 10,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $3.18, for a total value of $31,800.00. Following the completion of the transaction, the director directly owned 20,692 shares in the company, valued at approximately $65,800.56. The trade was a 32.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 11.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Legato Capital Management LLC bought a new position in shares of NeuroOne Medical Technologies during the 4th quarter worth approximately $34,000. Squarepoint Ops LLC acquired a new stake in NeuroOne Medical Technologies in the fourth quarter valued at approximately $36,000. Susquehanna International Group LLP acquired a new stake in NeuroOne Medical Technologies in the third quarter valued at approximately $47,000. XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies in the second quarter worth $51,000. Finally, Goldman Sachs Group Inc. purchased a new position in NeuroOne Medical Technologies in the first quarter worth $84,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.